GSK launches probe into Iraq bribery claims

LONDON (AP) — GlaxoSmithKline said Monday it has launched an investigation into allegations it bribed doctors in Iraq, as the pharmaceuticals giant remains embroiled in a major corruption scandal in China.

The company said it is probing allegations of "improper conduct in our Iraq business" after reports that it hired 16 doctors and pharmacists in Iraq as paid sales representatives at a time they continued working for the government.

"In total, we employ fewer than 60 people in Iraq in our pharmaceuticals operation and these allegations relate to a small number of individuals in the country," it said in a statement, adding: "We have zero tolerance for unethical or illegal behavior."

The claims, first published in the Wall Street Journal, came from a person reportedly familiar with GSK's Middle East operations. They allege that GSK paid for the doctors' expenses to attend international conferences, and that it pays other doctors high fees to give lectures in exchange for promoting its drugs. The claims date back to 2012.

The company said it first became aware of the new claims in Iraq earlier this year. GSK has been badly hit by a high-profile bribery probe in China, where authorities allege that four of its employees paid for doctors and hospitals to prescribe its drugs. The investigation is ongoing.

The company has distanced itself from the scandal, maintaining that the employees acted without its knowledge and that the vast majority of its staff plays by the rules. It has also promised to overhaul its worldwide sales and marketing practices. Last year, it said it would scrap individual sales targets and payments to doctors for attending conferences or promoting its products.

GSK said it believed the reforms would eliminate any perceived conflicts of interest.

Related Headlines

  • AstraZeneca shareholder urges Pfizer rethink

    AstraZeneca shareholder Schroders has urged the pharmaceutical firm to reconsider its rejection of a takeover offer from U.S. drugmaker Pfizer. The fund manager, which holds ... 

  • Pfizer underscores UK commitments in memo

    Pfizer Inc. has sought to allay concerns over its proposed $106 billion takeover offer of Anglo-Swedish pharmaceuticals firm AstraZeneca, insisting that its promises will be ... 

  • Ryan Falvey

    Stocks manage small gains; Dow, S&P 500 at records

    Stocks inched past more milestones Friday, delivering the third consecutive record-high close for the Standard & Poor's 500 index and a new high for the Dow Jones industrial ... 

  • Pfizer pulls plug on push to buy AstraZeneca

    Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the ... 

Find the best rates

Find your future job here